NCT00026182View on ClinicalTrials.gov

Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

October 31, 2001

Primary Completion Date

February 28, 2005

Conditions
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Small Lymphocytic LymphomaSplenic Marginal Zone Lymphoma
Interventions
BIOLOGICAL

rituximab

Given IV

BIOLOGICAL

recombinant interleukin-12

Given SC

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

questionnaire administration

Ancillary studies

PROCEDURE

quality-of-life assessment

Ancillary studies

Trial Locations (1)

55905

North Central Cancer Treatment Group, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00026182 - Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter